Navigation Links
Avicena's HD-02 to Proceed to NIH Sponsored Phase III Huntington's Disease Trial
Date:3/12/2008

PALO ALTO, Calif., March 12 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTC Bulletin Board: AVGO), a late stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases, announced today that it met with the Food and Drug Administration (FDA) and will proceed with a Phase III trial of its lead drug candidate, HD-02, for the treatment of Huntington's disease, pending final analysis of completed animal toxicology studies.

A double-blind, placebo-controlled Phase III clinical trial which will be led by Dr. Steven Hersch and Dr. Diana Rosas of Massachusetts General Hospital, Dr. Bernard Ravina of University of Rochester and the Huntington Study Group will evaluate the ability of HD-02 to slow functional decline in Huntington's disease patients as measured by the Total Functional Capacity (TFC) score. A Special Protocol Assessment will be submitted which will expedite FDA review. The trial will be sponsored by the National Center for Complementary and Alternative Medicine (NCCAM) of the National Institutes of Health (NIH) and the Orphan Product Division of the FDA. Enrollment is anticipated to begin in Q3 2008.

In previous studies, HD-02 has shown potential neuroprotective properties in Huntington's disease patients. Results from a Phase II clinical trial of HD-02, led by Dr. Steven Hersch, were published in the January 24, 2006 issue of Neurology and showed that HD-02 suppressed an oxidative damage marker, 8OH2DG, which is a measure of cellular injury. Also, in a dose escalation 2 year open-label study led by Dr. Steven Hersch and Dr. Diana Rosas of Massachusetts General Hospital, higher doses of HD-02 were observed to normalize 8OH2DG and stabilize clinical and radiological hallmarks of HD. These findings demonstrate the disease-modifying potential of HD-02 and provided the rationale for a Phase III study to further evaluate its efficacy.

"We are extremely pleased with the outcome of the FDA me
'/>"/>

SOURCE Avicena Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
2. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
3. Baxter to Proceed With Recall of Remaining Heparin Sodium Vial Products
4. Complete ANX-530 Safety Data to be Published in the 2008 Proceedings of the American Society of Clinical Oncology
5. CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
6. Arizona Pain Society and Dr. Robert Barkin, Rush University Medical Center, Present Program on Comprehensive Urine Drug Testing Sponsored by Dominion Diagnostics
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
11. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 Second generation biofuels are a ... fossil fuels. However, as natural gas is very cheap, this ... are not as valuable as they could be in comparison ... financing projects, has made it difficult for renewable energy developers ... off the ground. For these reasons, certain companies have shifted ...
(Date:7/29/2014)... July 29, 2014 A new ... market (types, applications and geography) - Size, Share, Global ... Segmentation and Forecast, 2013 - 2020", suggests that the ... billion by 2020 registering a CAGR of 11.1% from ... achieved by the electro surgical devices in operative procedures ...
(Date:7/29/2014)... & Rockville, MD (PRWEB) July 29, 2014 ... Inc. (ITI), a vaccine pioneer in the biotechnology ... services firm Newport Coast Securities, Inc. to explore ... is commercializing LAMP-vax technology, a breakthrough vaccine platform ... and immunotherapy market. The company exclusively licensed the ...
(Date:7/29/2014)... Carolina (PRWEB) July 29, 2014 DisasterTalk is ... of people where cell phone masts or other transmitters are ... to 100 feet away without the need for any Wi-Fi, ... longer ranges. , The new app has launched as a ... homes are at very high risk of being affected by ...
Breaking Biology Technology:Renewable Waste Intelligence: Could Renewable Chemicals Be the Future for the Renewable Energy Industry? 2Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 2Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 3Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3DisasterTalk App Could Save Lives as Report Reveals 8% of US Homes at Very High Risk of Natural Disaster 2
... Additional Phase 3 Trials on Track for Initiation Later ... for Today at 8:30 a.m. Eastern Time -, ... ARNA ) announced today that an independent Echocardiographic,Data Safety ... to stop,the ongoing pivotal Phase 3 trial, BLOOM (Behavioral ...
... Unit for $185 Million; Deal ... Expected to Close in the Fourth Quarter 2007, ... NABI ) announced today that it has entered into,a ... the Nabi,Biologics strategic business unit (SBU) to Biotest Pharmaceuticals,Corporation ...
... Ltd. (NASDAQ: XTLB ; LSE: XTL; TASE: XTL) ... 8:30 a.m. EDT to discuss the,Phase IIb clinical trial ... was initiated yesterday. Hosting the call will be ... will be two distinguished members of the diabetic,neuropathic pain ...
Cached Biology Technology:Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review 2Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review 3Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review 4Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review 5Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review 6Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG 2Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG 3Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG 4Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG 5Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG 6Reminder: XTL to Hold a Conference Call Today at 8:30 am EDT to Discuss the Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 2
(Date:7/29/2014)... Francisco is the first to show that while the ... aging, these negative effects may be reduced by maintaining ... "The study participants who exercised, slept well and ate ... didn,t maintain healthy lifestyles, even when they had similar ... assistant professor in the department of psychiatry at UCSF. ...
(Date:7/28/2014)... An international team of researchers led by the University ... rice. , The genetic information will enhance scientists, and ... as well as enable the development of new rice ... environmental stressors to help solve global hunger challenges. , ... Oryza glaberrima ) and evidence for independent domestication," was ...
(Date:7/28/2014)... School of Medicine have pinpointed a mechanism in part of ... the blood, linking it to both type 1 and type ... issue of Proceedings of the National Academies of Sciences ... located in a part of the hypothalamus known as ... motion that control glucose levels in the blood," said lead ...
Breaking Biology News(10 mins):Healthy lifestyle may buffer against stress-related cell aging, study says 2Generating a genome to feed the world: UA-led team sequences African rice 2Generating a genome to feed the world: UA-led team sequences African rice 3Generating a genome to feed the world: UA-led team sequences African rice 4Glucose 'control switch' in the brain key to both types of diabetes 2
... University Park, Pa. Health benefits from polyphenol antioxidants ... may come at a cost to some people. Penn ... the amount of iron the body absorbs, which can ... "Polyphenols have been known to have many beneficial effects ...
... biological invader that reaches its shores via cargo shipped ... Asian Longhorned Beetles, Kudzu, Triffid weed and others have ... harming human health and threatening biodiversity. The answer: ... of controlling invaders against the economic necessity of free ...
... brings debilitating side effects such as nausea, liver toxicity and ... way to deliver this life-saving therapy to cancer patients ― ... been invented by Dr. Dan Peer of Tel Aviv University,s ... Nano Science and Nano Technology together with Prof. Rimona Margalit ...
Cached Biology News:Polyphenol antioxidants inhibit iron absorption 2New analysis weighs lost trade, costs to control invasive species against economic damages 2New analysis weighs lost trade, costs to control invasive species against economic damages 3A cluster bomb for cancer care 2
US Pharmacopoeia Purified-Water/Water-for-Injection Quality Water...
... PinPoint™ Vector Sequencing Primer is designed for ... Vectors (Cat.# V2031, V2051, V2061). The primer ... at nucleotides 325343, approximately 4050 base pairs ... can be used to determine if an ...
Request Info...
...
Biology Products: